论文部分内容阅读
文章报告用国产格列齐特片治疗Ⅱ型糖尿病104例,每日用量40—320mg,以甲苯磺丁脲为对照(n=49),疗程3个月的疗效评价.对治疗前后糖代谢,血清胰岛素,糖化血红蛋白,血脂及血流变学等变化进行观察,结果提示本药适用于NIDDM患者,可增加胰岛β细胞功能,显著降低血糖等,不良反应轻微,优于甲苯磺丁脲类,属于安全有效,耐受性良好的国产第2代口服磺脲类降糖药.
The article reports the use of domestic gliclazide tablets in the treatment of 104 cases of type II diabetes mellitus, the daily dosage of 40-320mg, tolbutamide as a control (n = 49), the course of 3 months of efficacy evaluation of the glucose metabolism, Serum insulin, glycosylated hemoglobin, blood lipids and hemorheology changes were observed, the results suggest that the drug is suitable for NIDDM patients can increase pancreatic β-cell function, significantly lower blood sugar, mild adverse reactions, superior to tolbutamide, A safe, effective, well-tolerated domestic second-generation oral sulfonylurea hypoglycemic agents.